<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205917</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI T002</org_study_id>
    <nct_id>NCT03205917</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults</brief_title>
  <official_title>A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ragon Institute of MGH, MIT and Harvard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Health, Houston AIDS Research Team (HART)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orlando Immunology Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral
      efficacy of the PGDM1400 and PGT121 and VRC07-523LS mAbs for HIV prevention and therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral
      efficacy of the PGDM1400, PGT121 and VRC07-523LS mAbs for HIV prevention and therapy.
      PGDM1400, PGT121 and VRC07-523LS mAbs are recombinant human IgG1 monoclonal antibodies that
      target V1V2 (PGDM1400), a V3 glycan-dependent epitope (PGT121) and the CD4 binding site
      (VRC07-523LS) epitope region of the HIV envelope protein. PGT121, PGDM1400 and VRC07-523LS
      mAb were chosen for this study because of their potency, their ability to neutralize a wide
      array of cross-clade HIV viruses in a complementary pattern and their proven antiviral
      activity in animal studies e.g., their capacity to robustly prevent and treat simian-human
      immunodeficiency virus (SHIV) in rhesus monkeys.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>Proportion of participants with moderate or greater reactogenicity (e.g., solicited adverse events) for 3 days following IV infusion of PGDM1400 mAb alone, and a combination of PGDM1400 mAb and PGT121 mAb, and a combination of PGDM1400 mAb and PGT121 mAb and VRC07-523LS mAb
Proportion of participants with adverse events (AEs), including safety laboratory (biochemical, hematological) parameters, during the first 56 days following IV infusion of PGDM1400 mAb alone and a combination of PGDM1400 mAb and PGT121 mAb, and a combination of PGDM1400 mAb and PGT121 mAb and VRC07-523LS mAb, that are moderate or greater, and/or related to PGDM1400 mAb or PGT121 mAb or VRC07-523LS mAb
Proportion of participants with SAEs throughout the study period following IV infusion of PGDM1400 mAb alone and a combination of PGDM1400 mAb and PGT121 mAb, and a combination of PGDM1400 mAb and PGT121 mAb and VRC07-523LS mAb, that are related to PGDM1400 mAb or PGT121 mAb or VRC07-523LS mAb</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>Elimination half-life following IV infusion of PGDM1400 mAb alone or a combination of PGDM1400 mAb and PGT121 mAb in HIV-uninfected and HIV-infected adults; or a combination of PGDM1400 mAb and PGT121 mAb and VRC07-523LS mAb in HIV-infected adults</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL/F)</measure>
    <time_frame>6 months post infusion</time_frame>
    <description>Clearance following IV infusion of PGDM1400 mAb alone or a combination of PGDM1400 mAb and PGT121 mAb in HIV-uninfected and HIV-infected adults; or a combination of PGDM1400 mAb and PGT121 mAb and VRC07-523LS mAb in HIV-infected adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>6 months post infusion</time_frame>
    <description>Volume of distribution following IV infusion of PGDM1400 mAb alone or a combination of PGDM1400 mAb and PGT121 mAb in HIV-uninfected and HIV-infected adults; or a combination of PGDM1400 mAb and PGT121 mAb and VRC07-523LS mAb in HIV-infected adults</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration decay curve (AUC)</measure>
    <time_frame>6 months post infusion</time_frame>
    <description>AUC following IV infusion of PGDM1400 mAb alone or a combination of PGDM1400 mAb and PGT121 mAb in HIV-uninfected and HIV-infected adults; or a combination of PGDM1400 mAb and PGT121 mAb and VRC07-523LS mAb in HIV-infected adults</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of viral load and/or ART</measure>
    <time_frame>6 months post infusion</time_frame>
    <description>Impact of viral load and/or ART on PGDM1400 mAb and PGT121 mAb and VRC07-523LS mAb disposition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity of PGDM1400 in combination with PGT121 or PGDM1400 in combination with PGT121 and VRC07-523LS mAbs</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>Antiviral activity following IV infusion of PGDM1400 mAb in combination with PGT121 mAb, or PGDM1400 mAb in combination with PGT121 mAb and VRC07-523LS mAb, in viremic HIV-infected adults not on ART:
Change in plasma HIV-1 RNA levels from baseline (mean of pre-entry and entry values)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum antibody titers against bNAbs</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>Serum anti-PGDM1400 antibody titers, Serum anti-PGT121 antibody titers and Serum anti-VRC07-523LS antibody titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T cell count</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>Determine if IV infusion of PGDM1400 mAb in combination with PGT121 mAb, or PGDM1400 mAb in combination with PGT121 mAb and VRC07-523LS mAb, has any impact on CD4+ T cell counts in HIV-infected adults. Change in CD4+ T cell count compared to baseline as measured by single platform flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV genotyping of circulating virus</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>Compare plasma virus genotype activity before and after IV infusion of PGDM1400 mAb in combination with PGT121 mAb, or PGDM1400 mAb in combination with PGT121 mAb and VRC07-523LS mAb to determine if PGDM1400 mAb and PGT121 mAb and/or PGT121VRC07-523LS mAb induced viral escape mutations have developed in viremic HIV-infected adults not on ART
Genotypic analysis: Development of sequence variations in epitopes known to result in reduced PGDM1400 mAb and/or PGT121 mAb and/or VRC07-523LS mAb neutralization susceptibility or known to cause resistance to antiretroviral drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV phenotyping of circulating virus</measure>
    <time_frame>6 months post infusion</time_frame>
    <description>Compare plasma virus phenotypic activity before and after IV infusion of PGDM1400 mAb in combination with PGT121 mAb, or PGDM1400 mAb in combination with PGT121 mAb and VRC07-523LS mAb to determine if PGDM1400 mAb and PGT121 mAb and/or PGT121VRC07-523LS mAb induced viral escape mutations have developed in viremic HIV-infected adults not on ART. Phenotypic analysis: Changes in viral susceptibility to PGDM1400 mAb and/or PGT121 mAb and/or VRC07-523LS mAb neutralization
Phenotypic analysis: Changes in viral susceptibility to PGDM1400 mAb and/or PGT121 mAb and/or VRC07-523LS mAb neutralization.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1A HIV-Uninfected</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGDM1400 low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B HIV-Uninfected</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGDM1400 mid dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1C HIV-Uninfected</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGDM1400 high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A HIV-Uninfected</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGDM1400 + PGT121 low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B HIV-Uninfected</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGDM1400 + PGT121 mid dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2C HIV-Uninfected</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGDM1400 + PGT121 high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3A HIV-infected off ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGDM1400 + PGT121 + VRC07-523LS at 20mg/kg; HIV+ without ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3B HIV-infected off ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGDM1400 + PGT121 at high dose; HIV + without ART</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400/Placebo (3mg/kg IV)</intervention_name>
    <description>3/1 (6/2 if DLT)</description>
    <arm_group_label>Group 1A HIV-Uninfected</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400/Placebo (10mg/kg IV)</intervention_name>
    <description>3/1 (6/2 if DLT)</description>
    <arm_group_label>Group 1B HIV-Uninfected</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400/Placebo (30mg/kg IV)</intervention_name>
    <description>3/1 (6/2 if DLT)</description>
    <arm_group_label>Group 1C HIV-Uninfected</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)</intervention_name>
    <description>3/1 (6/2 if DLT)</description>
    <arm_group_label>Group 2A HIV-Uninfected</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)</intervention_name>
    <description>3/1 (6/2 if DLT);</description>
    <arm_group_label>Group 2B HIV-Uninfected</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)</intervention_name>
    <description>3/1 (6/2 if DLT)</description>
    <arm_group_label>Group 2C HIV-Uninfected</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)</intervention_name>
    <description>3 (max 9)</description>
    <arm_group_label>Group 3A HIV-infected off ART</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400 + PGT121 (MTD IV)</intervention_name>
    <description>3 (max 9)</description>
    <arm_group_label>Group 3B HIV-infected off ART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Groups 1 and 2 Inclusion Criteria:

          -  HIV-uninfected males or females age 18-50 years old

          -  Willing to maintain low risk behavior for HIV infection

        Groups 1 and 2 Exclusion Criteria:

        • Confirmed HIV-infection, pregnancy or lactation, significant acute or chronic disease and
        clinically significant laboratory abnormalities

        Group 3 Inclusion Criteria:

          -  HIV-infected males or females age 18-65 years old

          -  Not on antiretroviral therapy with HIV-1 RNA plasma level between 1,000 and 100,000
             copies/ml, CD4 cell count ≥ 300 cells/uL

        Group 3 Exclusion Criteria:

        • Significant acute or chronic medical condition other than HIV infection, and clinically
        significant laboratory abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Juelg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research, Ragon Institute of MGH, MIT and Harvard</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Stephenson, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://iavi.org</url>
    <description>IAVI Website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

